USFDA issues 3 observations at Visakhapatnam facility

Regulatory & Legal View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹1216.00

prior close

₹1211.10

announcement price

After-mkt

timing

Nifty 100market+1.3%-1.0% vs market

Pharmaceuticals peers, median of 172sector-0.6%+0.9% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty 100 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.6

15m

+0.7

30m

+1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2+1.3-1.0-0.6+0.9

Next day

+1.4+1.9-0.5-0.7+2.1

+2.2+0.9+1.3-1.9+4.1

+2.3+0.3+2.0-3.5+5.9

+1.9-0.2+2.1-4.4+6.3

+1.1-0.9+2.1-6.1+7.2

+7.7+0.0+7.7-2.9+10.6

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's informed exchanges that the USFDA completed a Pre-Approval Inspection at its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, from October 8 to 9, 2026. The USFDA issued a Form 483 with three observations. The company said it will respond to these observations within the stipulated timeline.

Likely market impact

Form 483 with few observations is generally a minor regulatory event, but USFDA actions can affect future product approvals.